Snapshot from Sep 18, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical data

Kazia paxalisib colorectal cancer data

Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Sep 01, 2026

Sentiment
40
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive preclinical data could boost investor sentiment for Kazia Therapeutics, potentially increasing its stock price as the company advances paxalisib into a Phase 2 trial. The news may also positively impact Merck & Co., whose Keytruda is part of the combination, and could influence the broader oncology immunotherapy market.

Biotechnology Pharmaceuticals Oncology

Kazia Therapeutics announced preclinical and translational data showing its lead asset, paxalisib, reduced tumor burden by 52% in MSS/pMMR colorectal cancer models, and adding paxalisib to an immunotherapy drug reduced tumor volume by an additional 50% compared to immunotherapy alone. The company also advanced a biomarker program and filed a new patent covering paxalisib's use in colorectal cancer. Kazia plans to launch a five-arm Phase 2 clinical trial evaluating paxalisib as monotherapy and in combination with pembrolizumab (Keytruda) versus standard of care in pre-treated MSS/pMMR metastatic colorectal cancer, with enrollment expected to begin in Q1 2027. The data suggests paxalisib may reprogram the tumor microenvironment to enhance immune visibility, potentially offering a first-in-class strategy for this patient population where checkpoint inhibitors have shown little benefit.

80 Kazia Therapeutics reported preclinical data
70 Kazia Therapeutics filed patent
stock
Kazia is the developer of paxalisib and the primary beneficiary of the positive preclinical data, which supports its advancement into a Phase 2 trial and strengthens its pipeline.
Importance 100.0 Sentiment 70.0
stock
Merck's Keytruda is used in combination with paxalisib in the planned trial; positive data could expand Keytruda's use in MSS/pMMR colorectal cancer, though the impact is indirect.
Importance 60.0 Sentiment 30.0
per
Sudha Rao, Chief Scientific Officer, is a key spokesperson and likely a driver of the scientific strategy behind paxalisib's development.
Importance 30.0 Sentiment 0.0
subs
F. Hoffmann-La Roche — Genentech originally licensed paxalisib to Kazia; the drug's progress may reflect positively on F. Hoffmann-La Roche — Genentech's early research, but F. Hoffmann-La Roche — Genentech has no direct involvement in this event.
Importance 20.0 Sentiment 10.0
govactor
The FDA has granted paxalisib various designations in other indications; this event does not involve new regulatory actions, but future trials may require FDA interaction.
Importance 15.0 Sentiment 0.0
stock
Evotec licensed EVT801 to Kazia, but this event focuses on paxalisib, so Evotec's role is minimal.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.